Wedge Capital Management L L P NC Sells 45,007 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wedge Capital Management L L P NC lessened its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 23.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 143,778 shares of the biopharmaceutical company's stock after selling 45,007 shares during the quarter. Wedge Capital Management L L P NC's holdings in Amicus Therapeutics were worth $1,173,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of FOLD. Virtus Fund Advisers LLC acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at $29,000. Covestor Ltd grew its holdings in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Amicus Therapeutics in the 4th quarter worth approximately $59,000. GAMMA Investing LLC boosted its stake in shares of Amicus Therapeutics by 1,610.8% during the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares in the last quarter. Finally, Sciencast Management LP purchased a new position in Amicus Therapeutics in the 4th quarter worth about $100,000.

Analyst Ratings Changes

FOLD has been the subject of several research analyst reports. Wells Fargo & Company reduced their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. UBS Group lifted their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.14 during trading hours on Friday, hitting $6.03. 4,224,896 shares of the company's stock were exchanged, compared to its average volume of 2,983,604. The stock's 50-day moving average is $6.48 and its 200-day moving average is $8.32. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -33.50, a price-to-earnings-growth ratio of 1.51 and a beta of 0.54. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.